ClinicalTrials.gg
RecruitingNCT07023289Updated Oct 9, 2026

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

A Phase 2 interventional study of Telisotuzumab Adizutecan and Standard of Care in Colorectal Cancer, sponsored by AbbVie. Recruiting at 48 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 9, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Colorectal Neoplasms by AbbVie — 4 open to participants now, 8 under way, 1 of them phase 3. Colorectal Neoplasms · AbbVie.

Planned enrollment
6th of 17
140 · median 101
Started
2025
with 1 other
Phase 2
5 of 17
2 open now
Registered
15th of 17
by date

Among the 17 studies in Colorectal Neoplasms by AbbVie, this one is the 6th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 2, and was the 15th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 17 studies in Colorectal Neoplasms by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Colorectal Neoplasms by AbbVie, or all of them as a file.
02

Study summary

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone.

Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. This study will be divided into two groups called treatment arms. In arm 1 participants will receive telisotuzumab adizutecan alone. In arm 2 participants will receive SOC alone. Approximately 140 adult participants with CRC will be enrolled in the study in 45 sites worldwide.

In arm 1, participants will receive intravenous (IV) doses of telisotuzumab adizutecan alone. In arm 2 Participants will receive SOC alone. The study will run for a duration of approximately 51 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal Cancer
  • Telisotuzumab Adizutecan
  • ABBV-400, Stand of Care
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed adenocarcinoma of the colon or rectum.
  • Surgical tumor material should be available for Signatera ctDNA personalized panel design.
  • Must have received at least 3 months of platinum-based doublet and/or neoadjuvant chemotherapy but may not have been treated with topoisomerase inhibitors as part of adjuvant therapy.
  • Has no radiographic evidence of disease (NED) confirmed by chest, abdominal, and pelvic computed tomography (CT) scans within 6 weeks prior to Cycle 1 Day 1 (C1D1) dosing.
  • Circulating tumor deoxyribonucleic acid (ctDNA) positive within 1 year either after the end of adjuvant therapy or after tumor resection in subjects who are receiving neoadjuvant therapy and begin treatment within 6 weeks after ctDNA positivity is confirmed (reported).
  • For participants with rectal cancer a total of at least 3 months of perioperative and/or adjuvant platinum-based doublet must have been administered. Please note that short course radiation or long-course chemoradiation does not count towards this 3-month minimum of platinum-doublet perioperative and/or adjuvant therapy.

Exclusion criteria

Exclusion Criteria:

  • No availability of surgical tissue sample.
  • History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic , or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Telisotuzumab Adizutecan Monotherapy

    Participants will receive telisotuzumab adizutecan dose A as a monotherapy, during the approximately 51 month study duration.

    Drug: Telisotuzumab Adizutecan

  • Active comparator
    Standard of Care (SOC)

    Participants will receive SOC, during the approximately 51 month study duration.

    Drug: Standard of Care

Interventions

  • Intravenous (IV) Infusion

  • DrugStandard of Care

    Standard of care treatment based on investigator's judgement to the active surveillance.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with disease free survival (DFS) Event

    DFS is defined as the time from randomization to the time of first occurrence of first radiographic recurrence of colorectal cancer (CRC), (either local recurrence or distant metastases) as determined by the investigator, or death from any cause.

    Time frame: Up to Approximately 51 Months

Secondary outcomes

  1. Change in Circulating Tumor Deoxyribonucleic Acid (ctDNA) Clearance at 6 months

    ctDNA clearance at 6 months is defined as ctDNA negative at 6 months after randomization.

    Time frame: 6 Months

  2. Overall Survival (OS)

    OS is defined as the time from randomization to the event of death from any cause.

    Time frame: Up to Approximately 51 Months

07

Study locations

47 of 48 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Nov 2029, 50 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 50 months is above that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jun 16, 2025
StartActual
Sep 2, 2025
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2029
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. Clearview Cancer Institute - Huntsville - Cci Drive /ID# 278621 is now Completed
Show site
  • University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275407 · Philadelphia, United States
Show 1 removed
  • Abramson Cancer Center at the University of Pennsylvania /ID# 275407 · Philadelphia, United States
across 2 updates, Oct 8, 2026 – Oct 9, 2026
Show all 2 updates
  1. Oct 9, 2026
    Clearview Cancer Institute - Huntsville - Cci Drive /ID# 278621 is now Completed
  2. Oct 8, 2026
    1 site added, 1 site removed
    Show site
    • University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275407 · Philadelphia, United States
    Show 1 removed
    • Abramson Cancer Center at the University of Pennsylvania /ID# 275407 · Philadelphia, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07023289
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 16, 2025
Start date
Sep 2, 2025
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Oct 9, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telisotuzumab adizutecan

Start the discussion